VIR – vir biotechnology, inc. (US:NASDAQ)
Stock Stats
News
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer [Yahoo! Finance]
Vir Biotechnology Announces Closing of Global Strategic Collaboration with Astellas for the Treatment of Prostate Cancer
Vir Biotechnology (VIR) had its "sell (d-)" rating reaffirmed by Weiss Ratings.
Vir Biotechnology Announces First Patient Dosed in Phase 1 Dose-expansion Cohorts Evaluating PSMA-targeted, PRO-XTEN® Dual-masked T-cell Engager VIR-5500 in Patients with Metastatic Prostate Cancer
Vir Biotechnology (VIR) had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a "buy" rating on the stock.
Form ARS Vir Biotechnology, Inc. For: Dec 31
Form DEFA14A Vir Biotechnology, Inc.
Form DEF 14A Vir Biotechnology, Inc. For: Dec 31
Form 8-K Vir Biotechnology, Inc. For: Apr 07
Form 4 Vir Biotechnology, Inc. For: Apr 06 Filed by: De Backer Marianne
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.